Cytokinetics (CYTK) Payables (2010 - 2026)

Cytokinetics (CYTK) has reported Payables for 17 consecutive years, with $54.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 111.8% year-over-year to $54.3 million; the TTM figure through Mar 2026 stood at $54.3 million (up 111.8% YoY), while the FY2025 annual figure was $53.4 million, up 68.74% from the prior year.
• Payables grew to $54.3 million in Q1 2026 per CYTK's latest filing, from $53.4 million in the prior quarter.
• Across five years, Payables topped out at $54.3 million in Q1 2026 and bottomed at $12.6 million in Q2 2023.
• Historically, Payables has averaged $25.7 million across 5 years, with a median of $22.7 million in 2024.
• Annual changes were most pronounced in 2022 — Payables jumped 155.42% — and 2024, when it slipped 25.29%.
• Cytokinetics' Payables stood at $25.6 million in 2022, then slipped by 16.02% to $21.5 million in 2023, then jumped by 47.25% to $31.7 million in 2024, then surged by 68.74% to $53.4 million in 2025, then rose by 1.63% to $54.3 million in 2026.
• Business Quant data shows CYTK's Payables at $54.3 million in Q1 2026, $53.4 million in Q4 2025, and $39.0 million in Q3 2025.